In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

Fintel reports that on December 9, 2025, BERENBERG upgraded their outlook for Novo Nordisk A (OTCPK:NONOF) from Hold to Buy. Analyst Price Forecast Suggests 54.52% Downside As of December 6, 2025, the ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

From weight loss percentages to steps and sleep, discover which health numbers actually matter. And why more isn't ...

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.

Upstart biotech company Viking Therapeutics (NASDAQ: VKTX) is a potential takeover candidate in 2026. That's not a reason to ...

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...